CA2306877A1 - Compositions d'insuline insolubles - Google Patents

Compositions d'insuline insolubles Download PDF

Info

Publication number
CA2306877A1
CA2306877A1 CA002306877A CA2306877A CA2306877A1 CA 2306877 A1 CA2306877 A1 CA 2306877A1 CA 002306877 A CA002306877 A CA 002306877A CA 2306877 A CA2306877 A CA 2306877A CA 2306877 A1 CA2306877 A1 CA 2306877A1
Authority
CA
Canada
Prior art keywords
acylated
insulin
fatty acid
human insulin
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002306877A
Other languages
English (en)
Inventor
Mark Laurence Brader
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2306877A1 publication Critical patent/CA2306877A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Abstract

La présente invention concerne des compositions insolubles contenant des protéines acylées, choisies dans le groupe constitué par l'insuline acylée, un analogue de l'insuline acylée, et la pro-insuline acylée; elle concerne également des formulations de ces compositions, conçues pour un apport parentéral ou d'autres moyens d'apport à un patient, aux fins d'une régulation accrue des taux de glycémie. L'invention concerne notamment des compositions comprenant une protéine acylée complexée avec du zinc, une protamine et un composé phénolique, de façon que le microcristal résultant soit analogue à la forme cristalline de l'insuline semilente Hagedorn (NPH). De manière étonnante, on a découvert que des compositions de telles protéines acylées possèdent des pharmacocinétiques de libération sous-cutanée supérieures sur le plan thérapeutique, ainsi que des glucodynamiques à profil plus étendu et plus plat, que celles de préparations d'insuline NPH, actuellement disponibles sur le marché. Par ailleurs, les cristaux de l'invention conservent certaines propriétés avantageuses des cristaux de NPH, en ce qu'ils peuvent être facilement remis en suspension et peuvent également être mélangés à des insulines solubles.
CA002306877A 1997-10-24 1998-10-22 Compositions d'insuline insolubles Abandoned CA2306877A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6310497P 1997-10-24 1997-10-24
US60/063,104 1997-10-24
US8893098P 1998-06-11 1998-06-11
US60/088,930 1998-06-11
PCT/US1998/022434 WO1999021578A1 (fr) 1997-10-24 1998-10-22 Compositions d'insuline insolubles

Publications (1)

Publication Number Publication Date
CA2306877A1 true CA2306877A1 (fr) 1999-05-06

Family

ID=26743043

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002306905A Abandoned CA2306905A1 (fr) 1997-10-24 1998-10-22 Analogues d'insuline acylee par un acide gras
CA002306877A Abandoned CA2306877A1 (fr) 1997-10-24 1998-10-22 Compositions d'insuline insolubles

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002306905A Abandoned CA2306905A1 (fr) 1997-10-24 1998-10-22 Analogues d'insuline acylee par un acide gras

Country Status (21)

Country Link
US (3) US6268335B1 (fr)
EP (1) EP1039920A4 (fr)
JP (2) JP2001521004A (fr)
KR (1) KR20010024556A (fr)
CN (1) CN1276731A (fr)
AR (1) AR020047A1 (fr)
AU (2) AU747926B2 (fr)
BR (1) BR9813111A (fr)
CA (2) CA2306905A1 (fr)
CO (1) CO4970769A1 (fr)
EA (1) EA200000453A1 (fr)
HR (1) HRP20000236A2 (fr)
HU (1) HUP0004169A3 (fr)
ID (1) ID24890A (fr)
IL (1) IL134901A0 (fr)
NO (1) NO20002038L (fr)
PE (1) PE123799A1 (fr)
PL (1) PL340255A1 (fr)
SV (1) SV1998000125A (fr)
TR (1) TR200001050T2 (fr)
WO (2) WO1999021578A1 (fr)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
WO2002051428A1 (fr) * 2000-12-25 2002-07-04 Shiseido Company, Ltd. Composition de parfum stimulant le systeme sympathique
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US20020155614A1 (en) * 2001-02-21 2002-10-24 Tomlinson Andrew J. Peptide esterification
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
EP1432430A4 (fr) * 2001-08-28 2006-05-10 Lilly Co Eli Pre-melanges de polypeptide glp-1 et d'insuline basale
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
CA2460867C (fr) * 2001-09-19 2011-04-12 Elan Pharma International Ltd. Preparations d'insuline nanoparticulaires
WO2003053460A1 (fr) * 2001-12-19 2003-07-03 Eli Lilly And Company Compositions cristallines pour reguler la glycemie
EP1545460A4 (fr) * 2001-12-20 2005-11-16 Lilly Co Eli Molecule d'insuline a duree d'action prolongee
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
JP2006519791A (ja) * 2003-03-13 2006-08-31 ノボ　ノルディスク　アクティーゼルスカブ 新規なｎｐｈインスリン製剤
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
SI1648933T1 (sl) * 2003-07-25 2010-01-29 Conjuchem Biotechnologies Inc Dolgo delujoäś inzulinski derivat in metoda zanj
EP1660531A2 (fr) 2003-08-05 2006-05-31 Novo Nordisk A/S Nouveaux derives de l'insuline
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス 単鎖インシュリン
BRPI0513508B1 (pt) 2004-07-19 2021-06-01 Biocon Limited Conjugados de insulina-oligômero, formulações e usos desses
CN101060856B (zh) 2004-11-22 2011-01-19 诺和诺德公司 可溶、稳定的含胰岛素制剂
EP1679065A1 (fr) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Formulation destinée à la libération contrôlée d'interferone par un copolymère bloc PEGT/PBT
US20100216690A1 (en) * 2005-03-18 2010-08-26 Novo Nordisk A/S Pegylated Single-Chain Insulin
EP1969004B1 (fr) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions renfermant une insuline acylée et du zinc et procédé de fabrication des dites compositions
WO2007081824A2 (fr) * 2006-01-06 2007-07-19 Case Western Reserve University Protéines résistantes à la fibrillation
WO2007121318A2 (fr) * 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Préparations destinées à l'administration d'insuline
JP2009536670A (ja) * 2006-05-10 2009-10-15 スミスクライン・ビーチャム・コーポレイション 化合物の細胞浸透性を増加させるための組成物および方法
WO2007135118A1 (fr) * 2006-05-24 2007-11-29 Novo Nordisk A/S Formules solubles stables contenant de l'insuline
JP5550338B2 (ja) 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー／エス ペグ化持続型インスリン
CA2663074A1 (fr) 2006-09-22 2008-03-27 Novo Nordisk A/S Analogues de l'insuline resistants a une protease
EP2074140B8 (fr) 2006-10-04 2015-10-28 Case Western Reserve University Insuline et analogues de l'insuline résistants à la fibrillation
EP2152245B1 (fr) 2007-04-30 2015-12-02 Novo Nordisk A/S Procédé de déshydratation d'une composition de protéine, composition de protéine déshydratée et composition pharmaceutique contenant la protéine déshydratée
WO2008152106A1 (fr) 2007-06-13 2008-12-18 Novo Nordisk A/S Formulation pharmaceutique contenant un dérivé d'insuline
KR20100053561A (ko) * 2007-08-15 2010-05-20 노보 노르디스크 에이/에스 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체
BRPI0818004B8 (pt) 2007-10-16 2021-05-25 Biocon Ltd composição farmacêutica sólida administrável por via oral e o processo da mesma.
KR20100111682A (ko) * 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
DE102008003566A1 (de) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
EP2229406B1 (fr) 2008-01-09 2015-04-22 Sanofi-Aventis Deutschland GmbH Nouveaux dérivés d'insuline à profil temporel/d'action extrêmement retardé
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
US8993516B2 (en) * 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
CA2722168A1 (fr) * 2008-04-22 2009-10-29 Case Western Reserve University Analogues de l'insuline specifiques a l'isoforme
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
KR20120129875A (ko) * 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
PT2349324T (pt) 2008-10-17 2017-12-06 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
WO2010049488A1 (fr) 2008-10-30 2010-05-06 Novo Nordisk A/S Traitement du diabète à l’aide d’injections d’insuline avec une fréquence inférieure à une injection par jour
AU2010208305A1 (en) 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
WO2010088294A1 (fr) 2009-01-28 2010-08-05 Smartcells, Inc. Systèmes à base de conjugués pour administration contrôlée de médicaments
US20100198188A1 (en) * 2009-02-05 2010-08-05 Abbott Diabetes Care Inc. Devices and Methods for Metering Insoluble Active Agent Particles
US8623345B2 (en) 2009-03-20 2014-01-07 Smartcells Terminally-functionalized conjugates and uses thereof
JP5675799B2 (ja) * 2009-07-06 2015-02-25 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 遅効性インスリン製剤
TW201105346A (en) * 2009-07-06 2011-02-16 Sanofi Aventis Deutschland Heat-stable and vibration-stable insulin preparations
US8399407B2 (en) * 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
PL2498802T3 (pl) 2009-11-13 2015-06-30 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
EP2498801B1 (fr) 2009-11-13 2018-01-24 Sanofi-Aventis Deutschland GmbH COMPOSITION PHARMACEUTIQUE COMPRENANT desPro36Exendin-4(1-39)-Lys6-NH2 ET DE LA MÉTHIONINE
CN102770152B (zh) 2009-11-25 2016-07-06 阿瑞斯根股份有限公司 肽类的粘膜递送
RU2012123642A (ru) * 2009-12-11 2014-01-20 Кейз Вестерн Ризев Юнивесити Аналоги инсулина, содержащие хлорированные аминокислоты
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
CA2802510A1 (fr) * 2010-06-23 2011-12-29 Novo Nordisk A/S Derives d'insuline contenant des liaisons disulfure supplementaires
EP2611458B1 (fr) 2010-08-30 2016-09-21 Sanofi-Aventis Deutschland GmbH Utilisation de lixisenatide pour fabrication de médicament pour traitement du diabète sucré de type 2
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2720711A1 (fr) 2011-06-15 2014-04-23 Novo Nordisk A/S Insulines à substitutions multiples
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
KR20150002777A (ko) 2012-04-11 2015-01-07 노보 노르디스크 에이/에스 인슐린 제제
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
EP3517122A1 (fr) 2013-04-03 2019-07-31 Sanofi Traitement du diabète sucré par des formulations à action prolongée d'insulines
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
PL3055325T3 (pl) 2013-10-07 2018-06-29 Novo Nordisk A/S Nowa pochodna analogu insuliny
US9839692B2 (en) 2014-01-09 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
JP6735674B2 (ja) 2014-01-09 2020-08-05 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
MX2016008978A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
JP2017532292A (ja) * 2014-08-11 2017-11-02 オルバニー メディカル カレッジ ミリストイル化レプチン関連ペプチド及びその使用
BR112017004544A2 (pt) 2014-10-06 2018-01-23 Univ Case Western Reserve insulina de cadeia simples, composição farmacêutica e método para tratar diabetes mellitus
EP3229828B1 (fr) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Formulation à rapport fixe d'insuline glargine/lixisenatide
CN105884879A (zh) * 2015-01-26 2016-08-24 漳州博欣生物技术有限公司 一种胰岛素类似物的化学合成方法
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
BR112018002416A2 (pt) * 2015-08-25 2018-09-18 Novo Nordisk As derivados de insulina e seus usos médicos
CN105597087B (zh) * 2016-01-06 2019-04-26 山东新时代药业有限公司 一种甘精胰岛素注射液及其制备方法
WO2018047062A1 (fr) 2016-09-06 2018-03-15 Chemical & Biopharmaceutical Laboratories Of Patras S.A. Dérivés de pro-insuline
EP4129321A1 (fr) 2016-12-05 2023-02-08 Nuritas Limited Compositions comprenant le peptide wkdeagkplvk
EP3329930A1 (fr) 2016-12-05 2018-06-06 Nuritas Limited Compositions pharmaceutiques
DK3554534T3 (da) 2016-12-16 2021-08-23 Novo Nordisk As Farmaceutisk sammensætning omfattende insulin
WO2018200462A1 (fr) * 2017-04-24 2018-11-01 Friedman Simon H Conjugués de médicament dotés de modulateurs de solubilité photoclivables
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
WO2019125879A2 (fr) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Systèmes à base de conjugués pour l'administration contrôlée d'insuline
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
EP3793568A4 (fr) * 2018-05-14 2022-01-19 Aerami Therapeutics, Inc. Formulations d'insuline destinées à une reconstitution en solutions liquides à concentration élevée
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
JP2022511567A (ja) 2018-12-11 2022-01-31 サノフイ インスリンコンジュゲート
CN110063932A (zh) * 2019-04-12 2019-07-30 浙江大学 一种多肽蛋白类药物的缓释组合物制剂及其制备方法
IL292762A (en) 2019-12-11 2022-07-01 Novo Nordisk As Innovative insulin analogs and their use
GB2610490A (en) 2020-03-31 2023-03-08 Protomer Tech Inc Conjugates for selective responsiveness to vicinal diols
JP7456007B2 (ja) 2020-05-15 2024-03-26 イーライ リリー アンド カンパニー 長時間作用アシル化インスリン化合物
TW202237188A (zh) 2020-11-19 2022-10-01 美商普羅托莫科技公司 芳族含硼化合物及胰島素類似物
EP4255469A1 (fr) * 2020-12-07 2023-10-11 Case Western Reserve University Analogues acylés de l'insuline à chaîne unique
US20230374045A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2801953A (en) 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US2849370A (en) 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US3060093A (en) 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
DE1793517C3 (de) 1968-09-28 1974-12-05 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt N(Al),N(B29>Bis-(tert.-butyloxycarbonyl)-insulin und Verfahren zu seiner Herstellung
US3950517A (en) 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
US3869437A (en) 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
GB1381274A (en) 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
US3865325A (en) 1971-07-02 1975-02-11 Dylaker Computer Systems Inc Flexible tape reel
US3907763A (en) 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
US4183849A (en) 1975-01-15 1980-01-15 Nordisk Insulinlaboratorium Therapeutic insulin preparation and a process for the production of a stable insulin preparation with protracted effect
JPS55138391A (en) 1979-04-13 1980-10-29 Shionogi & Co Ltd New synthetic method of peptide derivative
JPS55138393A (en) 1979-04-13 1980-10-29 Shionogi & Co Ltd Semisynthesis of insulin
US4343898A (en) 1980-02-11 1982-08-10 Novo Industri A/S Process for preparing esters of human insulin
DE3101382A1 (de) 1981-01-17 1982-09-02 Hoechst Ag, 6000 Frankfurt "verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten"
DK353781A (da) 1981-08-10 1983-02-11 Novo Industri As Fremgangsmaade til fremstilling af insulinderivater
IT1189353B (it) 1982-06-07 1988-02-04 Nordisk Insulinlab Procedimento per la preparazione di insulina umana e suoi esteri
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
US4946828A (en) * 1985-03-12 1990-08-07 Novo Nordisk A/S Novel insulin peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
JPH03506023A (ja) 1988-07-20 1991-12-26 ノボ　ノルデイスク　アクツイエセルスカプ ポリペプチド
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
DK134189D0 (da) 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
ATE176482T1 (de) 1993-06-21 1999-02-15 Novo Nordisk As Asp-b28-insulinkristalle
EP1132404A3 (fr) * 1993-09-17 2002-03-27 Novo Nordisk A/S Insuline acylée
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5597893A (en) 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
CZ289343B6 (cs) * 1995-03-17 2002-01-16 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek pro léčení diabetes
US5700904A (en) * 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5877153A (en) 1996-06-11 1999-03-02 Commonwealth Biotechnologies Inc. Heparin-binding peptides
BR9709844A (pt) 1996-06-20 1999-08-10 Novo Nordisk As Preparação aquosa de insulina formulação farmacêutica parenteral usos de um carboidrato n o-redutor ou reduzido e de manitol sorbitol xilitol inositol trealose sacarose ou qualquer sua mistura e processo de fabricação de uma preparação de insulina
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
EP0966482B1 (fr) 1997-02-07 2005-04-27 Novo Nordisk A/S Cristallisation de proteines
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.

Also Published As

Publication number Publication date
NO20002038D0 (no) 2000-04-18
US6465426B2 (en) 2002-10-15
AU1116699A (en) 1999-05-17
US20010036916A1 (en) 2001-11-01
EP1039920A4 (fr) 2003-05-28
NO20002038L (no) 2000-06-26
WO1999021573A1 (fr) 1999-05-06
EA200000453A1 (ru) 2000-10-30
IL134901A0 (en) 2001-05-20
HUP0004169A2 (hu) 2001-05-28
CN1276731A (zh) 2000-12-13
AR020047A1 (es) 2002-04-10
CO4970769A1 (es) 2000-11-07
CA2306905A1 (fr) 1999-05-06
PE123799A1 (es) 1999-12-13
HRP20000236A2 (en) 2001-02-28
BR9813111A (pt) 2000-08-15
WO1999021578A1 (fr) 1999-05-06
SV1998000125A (es) 1999-05-24
JP2001521004A (ja) 2001-11-06
EP1039920A1 (fr) 2000-10-04
TR200001050T2 (tr) 2000-08-21
AU747926B2 (en) 2002-05-30
AU1111799A (en) 1999-05-17
JP2001521006A (ja) 2001-11-06
US20020082199A1 (en) 2002-06-27
US6268335B1 (en) 2001-07-31
HUP0004169A3 (en) 2001-06-28
ID24890A (id) 2000-08-31
PL340255A1 (en) 2001-01-29
KR20010024556A (ko) 2001-03-26

Similar Documents

Publication Publication Date Title
US6465426B2 (en) Insoluble insulin compositions
EP0925792B1 (fr) Compositions insolubles d'insuline pour le contrôle du glucose sanguin
US20050176621A1 (en) Crystalline compositions for controlling blood glucose
EP0712861B1 (fr) Analogues d'insuline acylés
US5547929A (en) Insulin analog formulations
JP2002543092A (ja) 肺投与用インスリン結晶
CZ154395A3 (en) Insulin analogous protamine complex, process of its preparation and parenteral pharmaceutical composition containing thereof
US20050054818A1 (en) Crystalline compositions for controlling blood glucose
DeFelippis et al. Insulin self-association and the relationship to pharmacokinetics and pharmacodynamics
EP0969860B1 (fr) Procede de preparation d'une poudre therapeutique par co-precipitation d'insuline et d'un activateur de l'absorption
EP0911035A2 (fr) Compositions non solubles d' insuline
EP1396272A1 (fr) Compositions insolubles d'insuline pour le contrôle du glucose sanguin
MXPA00003955A (en) Insoluble insulin compositions
EP1196446A1 (fr) Compositions insuliniques acylees insolubles exemptes de protamine
CZ20002339A3 (cs) Nerozpustné kompozice pro ovlivňování glukózy v krvi
CZ20001492A3 (cs) Přípravky nerozpustného inzulínu
MXPA00006209A (en) Insoluble compositions for controlling blood glucose
AU734304B2 (en) Acylated insulin analogs

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued